Bigmar Announces Novuspharma Product for Clinical Trials

JOHNSTOWN, Ohio, April 4 /PRNewswire/ -- Bigmar, Inc.
(OTC Bulletin Board: BGMR), announced today that production for clinical
trials commenced under its supply agreement with Novuspharma.
Novuspharma is an Italian biotech firm specializing in novel cancer
therapies. The company has four anti-cancer products in clinical trials.
Bigmar currently manufactures BBR 2778 for Non-Hodgkins lymphoma and BBR
3464 for non small-cell lung cancer (US and Europe) and ovarian and gastric
cancers (Europe) under its supply agreement with Novuspharma.
Novuspharma anticipates the commencement of US Phase II trials in
pancreatic cancer patients in the near future.
Statements in this press release that are not strictly historical may be
"forward looking" statements, which involve risks and uncertainties. No
assurance can be given that the Company will successfully develop or
commercialize its products, complete clinical trials, obtain regulatory
approvals (or that and such approvals will be obtained on a timely basis) or
be able to manufacture or successfully commercialize such products. Actual
results may differ from those described in this press release due to risks and
uncertainties that exist in the Company's operations, including, without
limitation, the ability to obtain additional financing to continue operations
when needed, a history of operating losses and accumulated deficits, the
Company's reliance on collaborative relationships, and uncertainties related
to clinical trials, the ability to obtain the appropriate regulatory approvals
and market acceptance, as well as other risks detailed from time to time in
public available filings with the Securities and Exchange Commission such as
the Company's Annual Report on Form 10-KSB and its most recent Registration
Statement on Form S-3. Actual results may differ materially from those
currently anticipated as a result of such risks, and results for interim
periods are not necessarily indicative of results to be expected for the full
year. The Company undertakes no obligation to release publicly the results of
any revision to these forward-looking statements to reflect events or
circumstances arising after the date hereof. These statements are made
pursuant to the Safe Harbor provisions of the Securities Litigation Act of
1995.

SOURCE Bigmar, Inc.

JOHNSTOWN, Ohio, April 4 /PRNewswire/ -- Bigmar, Inc.
(OTC Bulletin Board: BGMR), announced today that production for clinical
trials commenced under its supply agreement with Novuspharma.
Novuspharma is an Italian biotech firm specializing in novel cancer
therapies. The company has four anti-cancer products in clinical trials.
Bigmar currently manufactures BBR 2778 for Non-Hodgkins lymphoma and BBR
3464 for non small-cell lung cancer (US and Europe) and ovarian and gastric
cancers (Europe) under its supply agreement with Novuspharma.
Novuspharma anticipates the commencement of US Phase II trials in
pancreatic cancer patients in the near future.
Statements in this press release that are not strictly historical may be
"forward looking" statements, which involve risks and uncertainties. No
assurance can be given that the Company will successfully develop or
commercialize its products, complete clinical trials, obtain regulatory
approvals (or that and such approvals will be obtained on a timely basis) or
be able to manufacture or successfully commercialize such products. Actual
results may differ from those described in this press release due to risks and
uncertainties that exist in the Company's operations, including, without
limitation, the ability to obtain additional financing to continue operations
when needed, a history of operating losses and accumulated deficits, the
Company's reliance on collaborative relationships, and uncertainties related
to clinical trials, the ability to obtain the appropriate regulatory approvals
and market acceptance, as well as other risks detailed from time to time in
public available filings with the Securities and Exchange Commission such as
the Company's Annual Report on Form 10-KSB and its most recent Registration
Statement on Form S-3. Actual results may differ materially from those
currently anticipated as a result of such risks, and results for interim
periods are not necessarily indicative of results to be expected for the full
year. The Company undertakes no obligation to release publicly the results of
any revision to these forward-looking statements to reflect events or
circumstances arising after the date hereof. These statements are made
pursuant to the Safe Harbor provisions of the Securities Litigation Act of
1995.
SOURCE Bigmar, Inc.